Proxy triplet trial of ACH-3102 and sovaprevir with sofosbuvir in patients with hepatitis C

Trial Profile

Proxy triplet trial of ACH-3102 and sovaprevir with sofosbuvir in patients with hepatitis C

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2015

At a glance

  • Drugs Odalasvir (Primary) ; Sofosbuvir; Sovaprevir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2015 According to a company media release, Achillion Pharmaceuticals expects to initiate this trial by early 2017.
    • 16 Mar 2015 New trial record
    • 05 Mar 2015 SVR4 results are expected in the second half of 2015, according to an Achillion Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top